Accueil・Liste d'Actions・Guardant Health Inc

Guardant Health Inc

Fermé

SecteurSoins de santé

162.59 -4.75

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

168.5

Max

170.69

Chiffres clés
By Trading Economics
Revenu	-8.1M -120M
Ventes	33M 335M
BPA	-0.89
Marge bénéficiaire	-35.866
Employés	2,490
EBITDA	-8.1M -109M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+12.23% upside

Dividendes
By Acuity
Prochains Résultats	28 oct. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	2.4B 22B
Ouverture précédente	167.34
Clôture précédente	162.59

Sentiment de l'Actualité

By Acuity

50%

147 / 340 Classement par Healthcare

Guardant Health Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 août 2026, 19:16 UTC

Guardant Health Inc shares are higher today, despite pulling back from an intraday high. The stock remains well above its 20-day moving average.

20 août 2026, 23:46 UTC

Guardant Health Inc. shares advanced in after-market trading, remaining above their 20-day moving average amid broader market pressures from rising crude oil prices.

19 août 2026, 20:02 UTC

Guardant Health Inc shares are higher today, supported by high trading volume. The stock remains above its 20-day moving average and near recent highs.

14 août 2026, 19:36 UTC

Guardant Health Inc shares are lower amid broader market sentiment following disappointing retail sales data, which may impact consumer demand and Federal Reserve interest rate policy.

13 août 2026, 23:36 UTC

Guardant Health shares are higher in after-market trading, though no specific news was identified. Broader market sentiment may be influenced by unchanged producer prices.

12 août 2026, 19:51 UTC

News

Guardant Health shares are lower as insider sales raise investor concerns. Director Ian Clark sold 14,180 shares for $2.3 million earlier this month.

10 août 2026, 19:36 UTC

Guardant Health Inc. shares are higher today, remaining above their 20-day moving average amid rising oil prices driven by geopolitical tensions.

7 août 2026, 20:03 UTC

Guardant Health Inc shares are advancing amid strong momentum and high trading volume. Broader market gains coincide with a decline in Treasury yields.

6 août 2026, 19:36 UTC

Guardant Health Inc shares are lower today, continuing a decline since Wednesday's close. No specific news was identified to explain the movement.

3 août 2026, 19:56 UTC

News

Guardant Health shares are higher as Stifel and Canaccord maintain Buy ratings, raising price targets to $180 and $205, respectively.

31 juil. 2026, 19:51 UTC

News

Social Media

Guardant Health Inc shares are trading higher as analysts raise price targets following strong second-quarter results and an upward revision of full-year revenue guidance.

30 juil. 2026, 23:21 UTC

News

Social Media

Guardant Health reported second-quarter revenue of $335 million, raising 2026 guidance to $1.34 billion to $1.36 billion, boosting shares in after-market hours.

29 juil. 2026, 18:54 UTC

Macro Event

News

Guardant Health Inc shares are higher as investors anticipate Q2 earnings on Thursday, following last quarter's revenue of $301.7 million, up 48.3% year-over-year.

28 juil. 2026, 19:16 UTC

News

Guardant Health shares are lower despite a tribute video featuring Patrick Dempsey and RBC's note on potential coverage tailwinds for the company.

27 juil. 2026, 19:36 UTC

News

Guardant Health Inc shares are lower, continuing a five-day decline despite a 48% year-over-year revenue increase and strong performance in the Shield segment.

24 juil. 2026, 18:36 UTC

Guardant Health Inc shares are lower today, continuing a decline since Thursday's close and remaining below the 20-day moving average.

20 juil. 2026, 20:02 UTC

News

Guardant Health Inc shares are lower today, continuing a decline since Friday amid mixed U.S. market performance and ongoing geopolitical tensions impacting investor sentiment.

Comparaison

Variation de prix

Guardant Health Inc prévision

Objectif de Prix

By TipRanks

12.23% hausse

Prévisions sur 12 Mois

Moyen 191.56 USD 12.23%

Haut 215 USD

Bas 125 USD

Basé sur 21 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

21 ratings

Achat

Maintien

Vente

Basé sur 21 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

147 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.